SK-UT-1 Cells

The SK-UT-1 cell line is derived from human uterine leiomyosarcoma (ULMS), a highly aggressive form of cancer originating in the smooth muscle of the uterus. This cell line is a key model for studying tumorigenesis, metastasis, and drug resistance in ULMS. SK-UT-1 cells exhibit features of sarcomas, including rapid proliferation, poor differentiation, and resistance to conventional therapies. In particular, they are used to investigate cancer stem-like cells (CSCs), which play a significant role in cancer recurrence and resistance to chemotherapy. Research has identified a subpopulation of CD133+ CSCs within SK-UT-1 cells, which demonstrate enhanced self-renewal, colony formation, and resistance to apoptosis. Studies using SK-UT-1 have focused on characterizing the CD133+ CSCs, revealing their ability to form tumorspheres, a feature indicative of stem cell-like behavior. This subpopulation shows increased tumorigenic potential in vivo, where even a small number of cells (104) are sufficient to initiate tumor formation in xenograft models. The CD133+ cells exhibit resistance to chemotherapeutic agents such as doxorubicin, which further supports their role in therapy resistance. Additionally, elevated levels of CSC-related markers, including CD44, ALDH1, and BMI1, were found in CD133+ cells compared to their CD133− counterparts, confirming their role as cancer stem cells. SK-UT-1 cells have become a vital tool in understanding ULMS progression and in developing potential therapeutic strategies. Targeting the CD133+ cancer stem-like cell population within these tumors may offer a promising approach to improve outcomes in patients with ULMS by addressing the root causes of metastasis and chemoresistance.